Concentraciones circulantes de MCP-1, VEGF-A, sICAM-1, sVCAM-1, sE-selectina y sVE-cadherina: su relación con componentes del síndrome metabólico en población joven / Circulating levels of MCP-1, VEGF-A, sICAM-1, sVCAM-1, sE-selectin and sVE-cadherin: Relationship with components of metabolic syndrome in young population

Introducción. La inflamación y disfunción endotelial son consideradas las primeras manifestaciones clínicas de la enfermedad cardiovascular. Diversos estudios han establecido una relación entre los componentes del síndrome metabólico (Smet), los marcadores de inflamación y la pérdida de la permeabilidad, la vasoconstricción y la vasodilatación endotelial. Objetivo. Determinar la relación entre la concentración de moléculas marcadores de disfunción endotelial, las citocinas inflamatorias y los componentes del Smet en población joven. Material y métodos. Estudio llevado a cabo en 240 estudiantes jóvenes-adultos con edades entre 18 y 28 años. Para definir la presencia de alteraciones clínicas y metabólicas se consideraron los criterios ATP-III modificados. A todos los estudiantes se les determinaron características sociodemográficas, parámetros antropométricos y perfil metabólico. Los niveles circulantes de MCP-1, VEGF-A, sICAM-1, sVCAM-1, sE-selectina y sVE-cadherina fueron determinados por inmunoanálisis ELISA (Bioscience). El análisis estadístico fue realizado utilizando el software STATA v. 9.2. Resultados. Del total de participantes en el estudio, el 44,6% presentó obesidad, el 59,9% obesidad abdominal, el 49,6% niveles bajos de c-HDL y el 16,7% niveles elevados de triglicéridos. El 16,25% de la población mostró al menos 3 componentes de Smet. Los niveles elevados de MCP-1, sICAM-1 y sE-selectina se asociaron a la presencia de obesidad. En un modelo ajustado por edad y género los niveles de MCP-1 y VEGF-A se asociaron a obesidad abdominal (OR=1,83; 1,02-3,28 y OR=2,03; 1,15-3,56; respectivamente), así como también a la presencia de 2 componentes de Smet. Los niveles de sVCAM-1 se asociaron a la alteración de la glucosa (OR=4,74; 1,32-17,0), sE-selectina a c-HDL bajo (OR=1,99; 1,05-3,75), mientras que sICAM-1 y sVE-cadherina se asociaron a la presencia de presión arterial sistólica alterada (OR=4,04; 1,24-13,1 y OR=6,28; 1,90-20,7, respectivamente). Conclusión. Los niveles circulantes de MCP-1 y VEGF-A se asociaron a adiposidad, los niveles de sVCAM-1 a la presencia de glucosa alterada, sE-selectina a c-HDL bajo, mientras que los niveles de sICAM-1 y sVE-cadherina se asociaron a presión arterial sistólica alterada en adultos jóvenes, independientemente de otros factores tradicionales de riesgo cardiovascular (AU)

Introduction. Inflammation and endothelial dysfunction are considered the primary manifestations of the cardiovascular disease. Studies have established a relationship among components of metabolic syndrome (MetS) with inflammatory markers and the loss of permeability, vasoconstriction and vasodilatation endothelial. Objective. To determine the relationship among the concentrations of soluble endothelial dysfunction molecules and inflammation cytokines and components of the metabolic syndrome in young population. Material and methods. A study was performed in 240 young adult students ages 18-28 years. To define the presence of clinical and metabolic alterations and MetS the modified ATP-III criteria was considered. In all subjects were determined sociodemographic characteristics, anthropometric measures and the metabolic profile. Circulating levels of MCP-1, VEGF-A, sICAM-1, sVCAM-1, sE-selectin and sVE-cadherin were determined by ELISA immunoassay (Bioscience). Statistical analysis was performed using STATA statistical software v. 9.2. Results. From all the participants, 44.6% had obesity, 59.9% had abdominal obesity, 49.6% low HDL-c and 16.7% high levels triglycerids. The 16.25% of the population showed 3 or more components of the MetS. Elevated MCP-1, sICAM-1 and sE-selectin levels were linked to the presence of obesity. In a model adjusted by age-gender, high soluble levels of MCP-1 and VEGF-A were linked with abdominal obesity (OR=1.83; 1.02-3.28 and OR=2.03; 1.15-3.56, respectively), as well as to the presence of the 2 components of MetS. sVCAM-1 levels were associated with impaired glucose (OR=4.74; 1.32-17.0); sE-selectin with low HDL-c (OR=1.99; 1.05-3.75), although sICAM-1 and sVE-cadherin were associated with impaired systolic blood pressure (OR=4.04; 1.24-13.1 and OR=6.28; 1.90-20.7, respectively). Conclusion. Levels of circulating MCP-1 and VEGF-A were associated with adiposity, levels of sVCAM-1 with the presence of impaired glucose, sE-selectin with low HDL-c, while the levels of sICAM-1 and sVE-cadherin were associated with impaired systolic blood pressure in young adults independently of other traditional risk factors (AU)

EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Objectives. The present study is to evaluate the expression level of enhancer of zeste homolog 2 (EZH2) and vascular endothelial growth factor (VEGF), and analyze their correlations with clinicopathological characteristics and survival in patients with clear cell renal cell carcinoma (CCRCC). The effect of EZH2 on apoptosis and cell proliferation in 786-O renal cancer cell line is investigated. Methods. The expression level of EZH2 and VEGF was detected in 185 primary CCRCC patients’ tissues using tissue microarray and immunohistochemistry. Small interfering RNA or enhanced green fluorescent protein transfection was employed to investigate the effect of EZH2 inhibition or overexpression on VEGF expression, apoptosis and cell proliferation in 786-O cells using flow cytometry, immunofluorescence microscopy, quantitative real-time reverse-transcription polymerase chain reaction and Western blot analysis. Results. High expression level of EZH2 and VEGF was observed in advanced CCRCC and correlated with the TNM stage (p = 0.013, p = 0.001) and distant metastasis (p = 0.011, p = 0.038), respectively. EZH2 was positively correlated with VEGF in CCRCC tissues (correlation coefficient = 0.850, p < 0.001). Kaplan–Meier survival analysis revealed that patients with positive EZH2 expression had a shorter overall survival time compared to patients with negative EZH2 expression (34.3 vs. 67.2, p < 0.001). In 786-O cells, EZH2 silencing inhibited VEGF expression and cell proliferation while increasing apoptosis (p < 0.001). EZH2 overexpression promoted VEGF expression and cell proliferation while inhibiting apoptosis (p < 0.001). Conclusions. EZH2 correlates positively with VEGF and associates with adverse clinicopathologic characteristics and shorter survival time in CCRCC patients. EZH2 accelerates antiapoptosis and cell cycle in 786-O cells (AU)

No disponible